282 related articles for article (PubMed ID: 32376796)
21. Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
Belyaeva E; Rubenstein A; Pierson SK; Dalldorf D; Frank D; Lim MS; Fajgenbaum DC
Hematol Oncol; 2022 Apr; 40(2):191-201. PubMed ID: 35104370
[TBL] [Abstract][Full Text] [Related]
22. TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.
Srkalovic G; Marijanovic I; Srkalovic MB; Fajgenbaum DC
Bosn J Basic Med Sci; 2017 May; 17(2):81-84. PubMed ID: 28135567
[TBL] [Abstract][Full Text] [Related]
23. TAFRO Syndrome.
Igawa T; Sato Y
Hematol Oncol Clin North Am; 2018 Feb; 32(1):107-118. PubMed ID: 29157612
[TBL] [Abstract][Full Text] [Related]
24. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.
Pierson SK; Stonestrom AJ; Shilling D; Ruth J; Nabel CS; Singh A; Ren Y; Stone K; Li H; van Rhee F; Fajgenbaum DC
Am J Hematol; 2018 Jul; 93(7):902-912. PubMed ID: 29675946
[TBL] [Abstract][Full Text] [Related]
25. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
[TBL] [Abstract][Full Text] [Related]
26. TAFRO syndrome is associated with anti-SSA/Ro60 antibodies, in contrast to idiopathic castleman disease.
Shirakashi M; Nishida Y; Nakashima R; Fujimoto M; Hiwa R; Tsuji H; Kitagori K; Akizuki S; Morinobu A; Yoshifuji H
Sci Rep; 2024 Feb; 14(1):2889. PubMed ID: 38311632
[TBL] [Abstract][Full Text] [Related]
27. TAFRO Syndrome: A Disease Requiring Immediate Medical Attention.
Masaki Y; Ueda Y; Yanagisawa H; Arita K; Sakai T; Yamada K; Mizuta S; Fukushima T; Takai K; Aoki S; Kawabata H
Intern Med; 2023 Jan; 62(1):27-32. PubMed ID: 35598998
[TBL] [Abstract][Full Text] [Related]
28. Tacrolimus Treatment for TAFRO Syndrome.
Shirai T; Ichikawa S; Saegusa J
Biomedicines; 2024 May; 12(5):. PubMed ID: 38791031
[TBL] [Abstract][Full Text] [Related]
29. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
Rubenstein AI; Pierson SK; Shyamsundar S; Bustamante MS; Gonzalez MV; Milller ID; Brandstadter JD; Mumau MD; Fajgenbaum DC
Br J Haematol; 2024 Mar; 204(3):921-930. PubMed ID: 38168727
[TBL] [Abstract][Full Text] [Related]
30. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
[TBL] [Abstract][Full Text] [Related]
31. Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease.
Nishikori A; Nishimura MF; Nishimura Y; Otsuka F; Maehama K; Ohsawa K; Momose S; Nakamura N; Sato Y
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142213
[TBL] [Abstract][Full Text] [Related]
32. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J
Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434
[TBL] [Abstract][Full Text] [Related]
33. TAFRO Syndrome: A Case of Significant Endocrinopathy in a Caucasian Patient.
Miatech JL; Patel NR; Latuso NQ; Ellipeddi PK
Cureus; 2019 Jun; 11(6):e4946. PubMed ID: 31453020
[TBL] [Abstract][Full Text] [Related]
34. Immunology and targeted therapy in Castleman disease.
Tsunoda S; Harada T; Kikushige Y; Kishimoto T; Yoshizaki K
Expert Rev Clin Immunol; 2024 May; ():1-12. PubMed ID: 38785062
[TBL] [Abstract][Full Text] [Related]
35. T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms.
Fraticelli S; Lucioni M; Neri G; Marchiori D; Cristinelli C; Merli M; Monaco R; Borra T; Lazzaro A; Uccella S; Arcaini L; Paulli M
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175521
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: a 6-year retrospective study.
Nishimura Y; Hanayama Y; Fujii N; Kondo E; Otsuka F
Intern Med J; 2020 Feb; 50(2):184-191. PubMed ID: 31211492
[TBL] [Abstract][Full Text] [Related]
37. Targeting the mTOR pathway in idiopathic multicentric Castleman disease.
Stern RM; Berliner N
J Clin Invest; 2019 Oct; 129(10):4086-4088. PubMed ID: 31524635
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease.
Iwaki N; Fajgenbaum DC; Nabel CS; Gion Y; Kondo E; Kawano M; Masunari T; Yoshida I; Moro H; Nikkuni K; Takai K; Matsue K; Kurosawa M; Hagihara M; Saito A; Okamoto M; Yokota K; Hiraiwa S; Nakamura N; Nakao S; Yoshino T; Sato Y
Am J Hematol; 2016 Feb; 91(2):220-6. PubMed ID: 26805758
[TBL] [Abstract][Full Text] [Related]
39. Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key.
Zhou QY
World J Clin Cases; 2022 Feb; 10(5):1536-1547. PubMed ID: 35211591
[TBL] [Abstract][Full Text] [Related]
40. Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.
Leurs A; Gnemmi V; Lionet A; Renaud L; Gibier JB; Copin MC; Hachulla E; Hatron PY; Launay D; Fajgenbaum D; Terriou L
Front Immunol; 2019; 10():1489. PubMed ID: 31316523
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
